Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT01329718

Specimens for Septin 9 Performance (SPR0012)

Specimen Collection Protocol for the Performance Evaluation of the Septin 9 Assay

Sponsor: Epigenomics, Inc

Updated 6 times since 2017 Last updated: Aug 1, 2014 Started: May 31, 2011 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Colorectal Cancer, this trial is completed. The trial is conducted by Epigenomics, Inc and has accumulated 6 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Epigenomics, Inc

Data source: Epigenomics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.